...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia
【24h】

Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia

机译：Inotuzumab ozogamicin用于治疗急性淋巴细胞白血病患者

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Inotuzumab ozogamicin is an antibody-drug conjugate comprised of a humanized anti-CD22 monoclonal antibody conjugated to calicheamicin, a cytotoxic antibiotic agent. Inotuzumab ozogamicin binds to CD22-expressing tumor cells, resulting in apoptotic cell death. Based on the results of the pivotal, phase III INO-VATE trial in acute lymphoblastic leukemia (ALL), approval of inotuzumab ozogamicin was recently granted for the treatment of patients with relapsed or refractory ALL, a group that otherwise has a poor prognosis with standard chemotherapy. Several ongoing clinical trials are now testing whether outcomes can be further improved by combining inotuzumab ozogamicin with low-dose chemotherapy or by including inotuzumab ozogamicin in the front-line setting. In this article we discuss the preclinical, clinical and safety data of inotuzumab ozogamicin.
机译：Inotuzumab ozogamicin是一种抗体 - 药物缀合物，其包含与Calicoxic抗生素缀合的人源化的抗CD22单克隆抗体，一种细胞毒性抗生素。 Inotuzumab ozogamicin与表达CD22的肿瘤细胞结合，导致凋亡细胞死亡。 基于急性淋巴细胞白血病（全部）的枢轴，III期III型反转试验的结果，最近批准oinuzumab ozogamicin的批准用于治疗复发或难治性的患者，这是一个否则标准预后差的组 化疗。 现在，几次持续的临床试验现在通过将inotuzumab ozogamicin与低剂量化学疗法组合或通过在前线设置中包含inotuzumab ozogamicin来测试结果是否可以进一步改善。 在本文中，我们讨论了inotuzumab ozogamicin的临床前，临床和安全数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号